All News
Here at Last: Treatment Options for VEXAS
We have known about the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome for nearly 3 years, but there has been relatively little to say about how to treat it. To date there have been over twice as many publications about VEXAS (263 publications) as there have been patients described with respect to treatment strategies (116 patients). One of the late breaking abstracts may finally have rectified this imbalance.
Read Article
Are Rheumatologists doing Enough for Cervical Cancer?
Should rheumatologists be counseling patients on cervical cancer prevention and screening?
Read Article
#Yr in #Preview #ACR2023 J Buyon
Pregnancies in #SLE have high #VTE risk - look at Ob/Gyn guidelines for prophylaxis of LMW #heparin - all SLE pregnancies recommend #ASA & #HCQ
biomarkers for #renal #lupus, #HCQ levels ?aid #Rx
-#SLE nephritis low prednisone
2 IS>1
@RheumNow
Janet Pope ( View Tweet)
B cell signalling reduction to treat #RA?
Telitacicept RCT showed #efficacy in active RA w MTX -maybe blunted high responses but no active comparator, only #PBO so difficult to compare to current Rx and only from 1 country China. Past bDMARDs not reported
L20 @RheumNow @ACRheum
Janet Pope ( View Tweet)
#Hope for people with #SLE
Insights from #ACR23
#Lupus #nephritis - half the oral #prednisone is = to 1 mg/kg induction after IV #solumedrol LESS PRED
#Anifrolimumab reduces similarly skin, jts, other common organs in #SLE RCTS APPROX 2X improvement vs PBO
@RheumNow @ACRheum https://t.co/OtdfTxZxr4
Janet Pope ( View Tweet)
As per #ACR23 ABST0433, what % of RA patients on US Medicare are on a DMARD within 1y of diagnosis?
I'm not talking your choice of b/tsDMARD.
I'm talking any cs/b/tsDMARD of any sort.
Hear from @JihaRheum to skip to the answer:
https://t.co/lI2M20JWKC
Truly stunning. @RheumNow
David Liew drdavidliew ( View Tweet)
Frail pts with SLE is associated with 🔸prolonged hospitalizations (28.89%), 🔸significantly higher in-pt mortality (2.88%)
🔸fewer days-to-readmission (59.8%)
vs. non-frail pts with SLE
(CLeung et al)
Screen your SLE pts for frailty too.
#ACR23 ABST2590 @RheumNow https://t.co/c4YP5h2ypn
sheila ( View Tweet)
INSIST trial: MMF vs Tac in SS-ILD
N=25 pts
👉No significant diff between MMF & TAC in mean change in FVC at 24 weeks [2.52%, 95% CI (-10.3 to 5.18)p=0.500]
👉No SAEs noted in both grps
Larger studies w/ longer ffup needed.
#ACR23 ABST2595 @RheumNow https://t.co/cqpnxyMDmv
sheila ( View Tweet)
I think crown belongs to the 🐱💜 🤗Top Influencers of #ACR23 👉 @ACRheum @rheum_cat @RheumNow @drdavidliew @EBRheum @realcc @KDAO2011 https://t.co/UfNdj8u7cP via @symplur https://t.co/b71OeZS7Jj
Lisa 🐳🗺🧭 rheumarhyme ( View Tweet)
Dr. @Janetbirdope has the best quotes ever ‘ if its ain’t broke, don’t fix it, just leave it alone’ 🤷🏻♀️
IGg4 is very interesting , could just be reacting / secondary to an underlying phenomenon?
https://t.co/hueCJuYI32
@RheumNow
#ACR23, Daily recap.
Nouf Al hemmadi ( View Tweet)
Sex bias in RA: time to stop blaming hormones?
https://t.co/uPq87r4Ndv https://t.co/Yleu2LDV3g
Dr. John Cush RheumNow ( View Tweet)
SpA Sleuths: The Case of Undiagnosed IBD #ACR23
As rheums, we are medical detectives investigating complex and often elusive autoimmune and inflammatory conditions.
https://t.co/eRxlaoohbi https://t.co/dtXcCXKXql
Dr. John Cush RheumNow ( View Tweet)
Watch: Another TYK2 Ticks the Boxes
Dr. Janet Pope discusses late-breaking abstract L12 presented at #ACR23.
https://t.co/1SGuIFOWt6 https://t.co/tb4LRbmfiI
Dr. John Cush RheumNow ( View Tweet)
#ACR23 – Day 1 Report
The day began with a bang with the Year in Review that featured the sage insights of Drs. Philip Seo and Tomas Mustelin about the scientific and clinical rheumatology highlights from the past year.
https://t.co/a79M2boHRH https://t.co/5P18ybazGK
Dr. John Cush RheumNow ( View Tweet)
Taylor et al. Novel blood assay for sero+ and sero- RA. Differentiates well from other diseases. May be very valuable for sero- RA diagnosis = sensitivity 83.7%, +LR 21.46, and -LR 0.17. Needs validation. Abstr#2586 #ACR23 @RheumNow https://t.co/jw41F8YohE https://t.co/kXi3km0b07
Richard Conway ( View Tweet)
Last abstract of #ACR23 was #ACRBest
Plasma cfDNA signatures (synovial mapped) to identify RA vs OA, other inflamm arthritis
Great performance, even with seroneg RA
A blood test to:
diagnose
?phenotype
?identify best b/tsDMARD
Could be massive
Peter Taylor ABST2586 @RheumNow https://t.co/tJX2jXV0Oe
David Liew drdavidliew ( View Tweet)
#ACRbest Yrin Preview @ACRheum
J Bathon
Take home
Symptomatic #Rx of ACPA+ people WITH #DMARD is too late to alter risk of #RA when drug is d/c
AI to read joint erosions on X-ray May be ‘too little too late’
#Steroids in #RA increase #MACE even after d/c
#ACR23 @RheumNow
Janet Pope ( View Tweet)
Identifying GCA diagnosis and disease activity through proteomics from plasma:
diagnosis looks good
disease activity looks harder
(Much like a lot of things in GCA, really)
Exciting work @MayoClinic @MdWarrington @jsung0906 #ACR23 ABST2601 @RheumNow https://t.co/SwxN58LieB
David Liew drdavidliew ( View Tweet)